NASDAQ:PRPO Precipio (PRPO) Stock Forecast, Price & News $5.60 +5.33 (+1,974.07%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.75▼$6.3550-Day Range$0.27▼$5.6052-Week Range$4.75▼$20.48Volume168,771 shsAverage Volume236,319 shsMarket Capitalization$154.34 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Precipio MarketRank™ ForecastAnalyst Rating0.00 Rating ScoreUpside/Downside64.3% Downside$2.00 Price TargetShort InterestHealthy0.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.85 out of 5 stars 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Precipio has a forecasted downside of 64.3% from its current price of $5.60.Amount of Analyst CoveragePrecipio has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.72% of the outstanding shares of Precipio have been sold short.Short Interest Ratio / Days to CoverPrecipio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precipio has recently decreased by 32.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecipio does not currently pay a dividend.Dividend GrowthPrecipio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPO. Previous Next 1.8 News and Social Media Coverage News SentimentPrecipio has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Precipio this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precipio insiders have not sold or bought any company stock.Percentage Held by Insiders10.60% of the stock of Precipio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.43% of the stock of Precipio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioPrecipio has a P/B Ratio of 7.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Precipio (NASDAQ:PRPO) StockPrecipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.Read More PRPO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRPO Stock News HeadlinesSeptember 22, 2023 | finanznachrichten.dePrecipio, Inc.: Precipio Takes Final Step Towards Regaining Nasdaq ComplianceSeptember 21, 2023 | americanbankingnews.comPrecipio (NASDAQ:PRPO) Share Price Crosses Below Two Hundred Day Moving Average of $0.49September 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 13, 2023 | finance.yahoo.comPrecipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of PlanSeptember 13, 2023 | americanbankingnews.comPrecipio (NASDAQ:PRPO) Stock Crosses Below Two Hundred Day Moving Average of $0.50August 20, 2023 | finance.yahoo.comBroker Revenue Forecasts For Precipio, Inc. (NASDAQ:PRPO) Are Surging HigherAugust 19, 2023 | finance.yahoo.comPrecipio, Inc. (NASDAQ:PRPO) Q2 2023 Earnings Call TranscriptAugust 16, 2023 | benzinga.comPrecipio's Earnings: A PreviewSeptember 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 13, 2023 | finance.yahoo.comPrecipio, Inc.'s (NASDAQ:PRPO) Shares Not Telling The Full StoryAugust 11, 2023 | finance.yahoo.comPrecipio Announces Q2-2023 Shareholder Update CallAugust 8, 2023 | finance.yahoo.comPrecipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 PanelAugust 3, 2023 | finance.yahoo.comPrecipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards BreakevenAugust 1, 2023 | investing.comEnd in sight for U.S. insider trading case over healthcare leaksAugust 1, 2023 | finance.yahoo.comPrecipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023July 6, 2023 | msn.comPrecipio (PRPO) Price Target Decreased by 29.82% to 2.04June 13, 2023 | finance.yahoo.comPrecipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® TechnologyJune 8, 2023 | msn.comWhy Oxford Industries Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJune 8, 2023 | marketwatch.comPrecipio Shares Slide Premarket on Sale of Equities >PRPOJune 8, 2023 | finance.yahoo.comPrecipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private PlacementJune 7, 2023 | finance.yahoo.comProjected cash burn reduced by $1.5 million annually from Three Operational Efficiency ProjectsMay 17, 2023 | msn.comPrecipio GAAP EPS of -$0.13 misses by $0.02, revenue of $2.82M beats by $0.02MMay 17, 2023 | finance.yahoo.comPrecipio Shares Growth Catalysts For HemeScreenMay 15, 2023 | finance.yahoo.comPrecipio Announces Q1-2023 Shareholder Update CallMay 4, 2023 | finance.yahoo.comPrecipio Signs Another HemeScreen™ CustomerMay 4, 2023 | finance.yahoo.comPrecipio Adds Substantial Pathology Customer to its Diagnostic Services DivisionApril 27, 2023 | finance.yahoo.comPrecipio Granted 180-day Extension From NASDAQ To Regain ComplianceSee More Headlines Receive PRPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPO Company Calendar Last Earnings8/11/2023Today9/23/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRPO CUSIPN/A CIK1043961 Webwww.precipiodx.com Phone(203) 787-7888Fax402-452-5401Employees53Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside-64.3%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,200,000.00 Net Margins-98.50% Pretax Margin-98.38% Return on Equity-68.54% Return on Assets-51.39% Debt Debt-to-Equity Ratio0.01 Current Ratio0.92 Quick Ratio0.81 Sales & Book Value Annual Sales$9.41 million Price / Sales16.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book7.78Miscellaneous Outstanding Shares27,560,000Free Float24,640,000Market Cap$154.34 million OptionableNot Optionable Beta2.03 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ilan Danieli (Age 51)Founder, Pres, CEO & Director Comp: $324.1kDr. Ayman A. Mohamed M.D. (Age 38)Chief Technology Officer Comp: $234.1kMr. Matthew Gage (Age 56)Interim Chief Financial Officer Mr. Ahmed Zaki Sabet (Age 36)Chief Operating Officer Ms. Miri Chiko-RadomskiChief Legal Counsel & People OfficerKey CompetitorsTalis BiomedicalNASDAQ:TLISSingular Genomics SystemsNASDAQ:OMICMonopar TherapeuticsNASDAQ:MNPRInnovative EyewearNASDAQ:LUCYXenetic BiosciencesNASDAQ:XBIOView All CompetitorsInsiders & InstitutionsWalleye Capital LLCBought 2,325,081 shares on 8/15/2023Ownership: 9.919%Richard A SandbergBought 20,000 shares on 1/20/2023Total: $15,600.00 ($0.78/share)Ilan DanieliBought 16,500 shares on 1/3/2023Total: $9,900.00 ($0.60/share)Ahmed Zaki SabetBought 750 shares on 1/3/2023Total: $450.00 ($0.60/share)Ilan DanieliBought 11,000 shares on 10/3/2022Total: $9,570.00 ($0.87/share)View All Insider TransactionsView All Institutional Transactions PRPO Stock - Frequently Asked Questions What is Precipio's stock price forecast for 2023? 0 Wall Street analysts have issued 1-year target prices for Precipio's shares. Their PRPO share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 64.3%. View analysts price targets for PRPO or view top-rated stocks among Wall Street analysts. How have PRPO shares performed in 2023? Precipio's stock was trading at $0.5514 on January 1st, 2023. Since then, PRPO shares have increased by 915.6% and is now trading at $5.60. View the best growth stocks for 2023 here. Are investors shorting Precipio? Precipio saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 198,400 shares, a drop of 33.0% from the August 15th total of 295,900 shares. Based on an average trading volume of 173,200 shares, the days-to-cover ratio is currently 1.1 days. View Precipio's Short Interest. When is Precipio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our PRPO earnings forecast. How were Precipio's earnings last quarter? Precipio, Inc. (NASDAQ:PRPO) posted its quarterly earnings data on Friday, August, 11th. The biotechnology company reported ($0.09) EPS for the quarter. The biotechnology company had revenue of $3.53 million for the quarter. Precipio had a negative net margin of 98.50% and a negative trailing twelve-month return on equity of 68.54%. When did Precipio's stock split? Precipio's stock reverse split on Friday, September 22nd 2023. The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Precipio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX). What is Precipio's stock symbol? Precipio trades on the NASDAQ under the ticker symbol "PRPO." Who are Precipio's major shareholders? Precipio's stock is owned by a number of retail and institutional investors. Top institutional investors include Walleye Capital LLC (9.92%). Insiders that own company stock include Ahmed Zaki Sabet, David Seth Cohen, Ilan Danieli and Richard A Sandberg. View institutional ownership trends. How do I buy shares of Precipio? Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Precipio's stock price today? One share of PRPO stock can currently be purchased for approximately $5.60. How much money does Precipio make? Precipio (NASDAQ:PRPO) has a market capitalization of $154.34 million and generates $9.41 million in revenue each year. How can I contact Precipio? Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The official website for the company is www.precipiodx.com. The biotechnology company can be reached via phone at (203) 787-7888, via email at investors@precipiodx.com, or via fax at 402-452-5401. This page (NASDAQ:PRPO) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precipio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.